Request for Information - Enhancing Pharmacy Countermeasures in Independent Pharmacies
ID: ICATT-2025-0001Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFCENTERS FOR DISEASE CONTROL AND PREVENTIONCDC OFFICE OF ACQUISITION SERVICESATLANTA, GA, 30333, USA

NAICS

Process, Physical Distribution, and Logistics Consulting Services (541614)

PSC

SUPPORT- MANAGEMENT: OTHER (R799)

Original Source

https://sam.gov/opp/71620c43294849d1b9d4e191c01c4538/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking insights through a Request for Information (RFI) aimed at enhancing pharmacy countermeasures in independent pharmacies. The objective is to gather information from pharmacy partners, vendors, and associations regarding the necessary capabilities and infrastructure for independent pharmacies to effectively deliver health services, including testing, vaccines, and therapeutics, particularly to under-resourced populations. This initiative is crucial as independent pharmacies play a vital role in public health, especially in rural areas, and the information collected will inform strategies to improve service delivery and public health response capacity. Interested parties can contact Dawn Redman at dredman@cdc.gov or call 404-498-3069 for further details.

    Point(s) of Contact
    Dawn Redman
    (404) 498-3069
    dredman@cdc.gov
    Files
    Title
    Posted
    RFI - Independant Pharm Appendix A.pdf
    The document outlines essential capabilities and infrastructure that independent pharmacies must develop to effectively provide pharmacy countermeasures. Key areas of focus include program management, staffing, and staff training, as well as ensuring compliance with regulations such as obtaining a CLIA Certification of Waiver. Pharmacies need to establish IT systems for patient management and public health reporting, alongside maintaining a quality control framework and selecting appropriate tests and vaccines. Additionally, reimbursement strategies for both insured and uninsured patients require attention, involving billing avenues and claim reconciliations. Local marketing, community engagement, and patient education are also highlighted as important components for the pharmacies to enhance service delivery. This working list serves as guidance for meeting public health needs through improved pharmacy capabilities, relevant to federal and state/local RFP contexts.
    Similar Opportunities
    FY25 Bulk Pharma Buy (Materiel)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The primary objective is to identify suppliers capable of providing FDA-approved medications, including Amoxicillin, Ciprofloxacin, and Clindamycin, in specified formulations and quantities, as detailed in the associated RFI documents. This procurement is crucial for ensuring rapid access to essential medical supplies during public health emergencies, such as biological or chemical threats and natural disasters. Interested vendors must submit their capabilities and relevant information electronically by January 9, 2025, to Terri Reed at terri.reed@hhs.gov, with the understanding that responses will not be returned and will be treated as public knowledge.
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information regarding domestic production capabilities related to anti-microbials under the Defense Production Act Title III Program. The objective of this Request for Information (RFI) is to identify gaps in the Public Health Industrial Base (PHIB) and enhance national defense resources by focusing on the production of essential medicines and medical countermeasures sourced domestically. Respondents are encouraged to share insights on their manufacturing processes, regulatory compliance, and infrastructure, as well as past supply chain disruptions and investment needs, with responses due by January 6, 2025, at 10 AM ET. Interested parties should submit their responses to Chris Newell at IBMSC-Submissions@hhs.gov.
    Safe Medication Use
    Active
    Health And Human Services, Department Of
    The U.S. Food and Drug Administration (FDA) is conducting a Request for Information (RFI) to identify potential sources capable of providing medication error reports, an analytics platform, and related services aimed at preventing and analyzing medication errors. This initiative, led by the FDA's Center for Drug Evaluation and Research, seeks organizations that can supply nationwide data from healthcare providers, consumers, and patient safety organizations, emphasizing the importance of robust reporting, data analysis, and training in enhancing medication safety protocols. Interested parties, particularly small businesses, are encouraged to submit their capability statements by January 6th, 2025, and should note that responses are voluntary and do not imply a commitment for a contract. For further inquiries, contact Brian Wodzisz at Brian.Wodzisz@fda.hhs.gov or call 301-796-7376.
    CDC DFWED NARST Sensititre Supplies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking to award a sole source contract for antimicrobial resistance testing supplies, specifically Sensititre™ broth microdilution testing products, from ThermoFisher Scientific. This procurement is essential for the National Antimicrobial Resistance Monitoring System (NARMS), which has utilized these proprietary materials since 1996 to ensure a standardized approach to monitoring enteric bacteria resistance. The unique nature of these supplies necessitates this sole source approach, as alternatives would require significant investments in new equipment and validation processes, potentially disrupting critical surveillance efforts. Interested parties may respond within 15 days to express their interest, with proposals directed to contract specialist Ashley Williams at dal3@cdc.gov.
    Pre-Solicitation FY 2025 CDC OS Emerging Public Health Priorities BAA
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is preparing to issue a Fiscal Year 2025 Broad Agency Announcement (BAA) for Applied Research aimed at addressing Emerging Public Health Priorities. This initiative seeks innovative research proposals in various areas, including infectious disease surveillance, wastewater surveillance, and substance use disorder recovery, to enhance public health strategies and responses to emerging threats. The BAA will be open for full and open competition, with a tentative issuance date of December 30, 2024, and a due date for concept papers set for January 30, 2025. Interested contractors must ensure they are registered in the System for Award Management (SAM) to be eligible for award, and further details will be available on SAM.gov.
    Phase I - Serological Assays for the detection and characterization of influenza viruses
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking contractors for a Phase I project focused on developing serological assays for the detection and characterization of influenza viruses. The contract entails a 12-month base period with four additional 12-month option periods, aimed at testing immunological responses from human samples collected during vaccine effectiveness studies and outbreak investigations using Hemagglutination Inhibition (HAI) assays. This initiative is critical for enhancing the understanding of influenza vaccine efficacy and ensuring public health safety. Interested parties can contact Jennifer Gartzke at jgartzke@cdc.gov or by phone at 404-498-0020 for further details, as this opportunity is open for full competition due to previous insufficient small business participation.
    Retail Pharmaceutical Prescription Fulfillment for Nashville Area Office Patients
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Indian Health Service, is seeking proposals for a Retail Pharmaceutical Prescription Fulfillment contract aimed at serving patients in the Nashville Area Office. This initiative is designed to enhance healthcare access for Native American communities by partnering with local pharmacies to provide primary and supplemental prescription coverage. The selected vendors will not only fulfill pharmaceutical needs but also contribute to corporate social responsibility efforts, promoting health equity within these communities. Interested parties can reach out to Paul Carr at paul.carr@ihs.gov or 615-467-1567 for further details, as the solicitation number is 285-25-RFQ-0001, with awards expected to be made following the presolicitation phase.
    DHS CWMD Research and Development Division (RDD) Biodetection and Bioidentification Timeliness Study
    Active
    Homeland Security, Department Of
    The Department of Homeland Security's Countering Weapons of Mass Destruction Office (CWMD) is seeking information from industry partners for a study focused on the timeliness of detection and response to intentional biological threat releases. The primary objective of this study is to develop and evaluate metrics that measure the effectiveness and timeliness of response processes and systems in mitigating biological threats, taking into account various operational environments and biological factors. This initiative is crucial for enhancing the United States' capabilities in biothreat detection and response, ultimately aiming to improve public health and safety outcomes. Interested parties are encouraged to submit their capabilities, proposed methodologies, timelines, and costs to Kevin Schwertfeger at kevin.schwertfeger@hq.dhs.gov or Darnell Griffin at darnell.griffin@hq.dhs.gov, as this Request for Information (RFI) does not guarantee a future Request for Proposal (RFP).
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Storage of NHANES Biospecimen Samples
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking proposals from qualified small businesses for the storage and management of approximately 500,000 NHANES biospecimen samples. The contractor will be responsible for receiving, storing, and shipping samples, as well as providing additional services such as freezer maintenance, inventory management, reporting, sample disposal, and decontamination. This procurement is critical for maintaining the integrity of public health research and data collection efforts, with a contract expected to be awarded as a Firm Fixed Price Indefinite Delivery/Indefinite Quantity (IDIQ) type, including a one-year base period and four one-year option periods. Interested parties must ensure they have an active registration in the System for Award Management (SAM) and are encouraged to submit proposals following the anticipated solicitation posting on SAM.gov around December 09, 2024. For further inquiries, contact Amy Holder at zts0@cdc.gov or Arianna Williams at xsm2@cdc.gov.